FEB 27, 2019 6:07 PM PST

Anti-Inflammatory Meds without Side Effects, Please

WRITTEN BY: Nicholas Breehl

Drugs such as ibuprofen or aspirin that relieve pain and lower fever are among the most frequently used drugs worldwide. These medicines aid in mitigating inflammation. However, in spite of their indisputable effectiveness and frequent use, we do not yet fully understand the underlying mechanisms of these drugs. In addition, when these drugs are taken, serious side effects occur and again, the causes of which have also not been sufficiently clarified.

The research team led by pharmacists Dr. Jana Gerstmeier and Prof. Oliver Werz of the University of Jena has developed a cell model with which they can find answers to these questions. As the team's scientists report in the specialist publication, 'The FASEB Journal,' they have succeeded in clarifying the complex effect of active compounds that are administered on the formation of endogenous signaling substances in immune cells during an inflammatory reaction. In the future, this will make it possible to develop new active drugs with fewer side effects. Working groups from Harvard Medical School in Boston and the Karolinska Institute in Stockholm were also involved in the research work.

Inflammation occurs in two phases.

"Inflammation proceeds -- roughly speaking -- in two successive phases," explains Markus Werner, a doctoral student at the Chair of Pharmaceutical and Medical Chemistry of Jena University and first author of the study. During the initial phase, type 'M1' immune cells (macrophages) are active. They produce inflammatory messenger substances (prostaglandins and leukotrienes) from unsaturated fatty acids, which trigger typical symptoms such as fever and pain. After a few days, the second phase begins, in which the inflammation is resolved. In this phase, type 'M2' macrophages are active, which produce inflammation-resolving messenger substances from the fatty acids (called resolvins).

"Conventional drugs intervene equally in both phases," says Dr. Jana Gerstmeier. "They reduce the production of both proinflammatory messenger substances and inflammation-resolving mediators." This alleviates the first acute inflammatory reaction, but at the same time, it also hampers the second phase in which the inflammation resolves. "There is a risk of inflammation not being stopped and continuing to progress so that secondary diseases occur." Ideally, drugs should, therefore, reduce only the acute phase, but not impair the period in which the inflammation resolves.

The special feature of the methodology is its sensitivity

The newly developed cell model enables researchers to investigate the efficacy of drugs in both inflammatory phases. "For this purpose, we use human immune cells (M1 and M2), which we pre-treat with the drug to be tested before inducing an inflammatory reaction using pathogenic bacteria," explains Jana Gerstmeier. The messenger substances released by the cells are analyzed.

The distinctive feature of the methodology developed in Jena is its sensitivity: the inflammation-resolving substances of the second phase are useful in concentrations about 1,000 times lower than the inflammatory signal substances of the first inflammatory phase. Very sensitive analytics is required to be able to detect these substances, and the Jena laboratory is one of the few laboratories in the world to have mastered this methodology. Using a mass spectrometer, several dozen mediator molecules that have been released are detected, and an individual spectrum is created for each active ingredient. This allows conclusions to be drawn about the influence of the drug on the entire inflammatory process.

Sources: Science Daily, FASEB, YouTube

About the Author
You May Also Like
OCT 21, 2019
Drug Discovery & Development
OCT 21, 2019
Effective Vaccines for Lyme Disease?
Currently, there are no effective vaccines available for the presentation of Lyme disease. The only preventive efforts present includes “guiding&rdqu...
DEC 05, 2019
Drug Discovery & Development
DEC 05, 2019
New Injection that Treats Peanut Allergy
Peanut allergies affect between 1 and 3% of the US population. Associated with a heightened risk of severe anaphylactic reactions, oral immunotherapy is th...
DEC 17, 2019
Immunology
DEC 17, 2019
Increased Belly Fat with Aging Linked to Reduced Mental Flexibility
Did you ever consider that your brain can flex similarly to the way your biceps can? Sure, brain flexing is more abstract and less literal, but the concept...
FEB 06, 2020
Drug Discovery & Development
FEB 06, 2020
China Begins Trials for Antiviral Drug to Tackle Coronavirus
So far, coronavirus has infected over 31,493 people globally, and has killed 638. Although 1,563 people have reportedly recovered, due to its fast-spreadin...
FEB 21, 2020
Drug Discovery & Development
FEB 21, 2020
New Antibiotics Found Using AI Technology
Using AI, researchers at MIT have found a powerful new antibiotic capable of killing some of the most dangerous drug-resistant bacteria known to man. ...
MAR 19, 2020
Drug Discovery & Development
MAR 19, 2020
Could a 1949 Malaria Drug Treat COVID-19?
In the race to halt the current coronavirus pandemic, scientists, health experts and even Elon Musk are considering chloroquine, a drug that has been used ...
Loading Comments...